Panel of circulating antigens as blood-based biomarkers of colon adenoma and colon adenocarcinoma

Description:

Biomarkers for Colon Cancer

Validated 5-protein panel for early detection of colon cancer and adenoma.

Dr. Lampe’s laboratory has identified and validated a five protein panel for early detection of adenoma and colon cancer: BAG4, IL6ST, VWF, EGFR and glycosylated CD44. This biomarker panel has been confirmed in two independent studies of patient plasma samples in a custom high-dimensional antibody microarray containing 3,200 different antibodies: (i) pre-diagnostic plasma samples from 79 individuals diagnosed with colon cancer less than 3 years following sample collection and 79 cancer-free controls and (ii) 120 plasma samples from people diagnosed with adenoma or cancer, and 60 controls. This biomarker panel has the potential to revolutionize the diagnosis of colon cancer. The panel has a specificity of 90% and sensitivities of 83-89% (adenoma) and 86-95% (cancer).

<ul>

<li>Colon cancer</li>

<li>Adenoma</li>

</ul>

<ul>

<li>Minimally invasive colon cancer screening mechanism</li>

<li>Can be worked into routine laboratory work</li>

<li>Early detection of adenoma and colon cancer</li>

</ul>

Colon cancer is the third leading cause of cancer-related deaths in the United States and approximately 150,000 new cases are diagnosed each year. Early detection drastically increases the odds of survival. The global colorectal cancer market size was worth USD 16.11 billion in 2023. This value is forecasted to grow at a CAGR of 2.63% to reach USD 18.34 billion by 2028.

Paul Lampe, PhD, Public Health Sciences

Development of multiplex assay for high throughput testing

US 10,866,239

14-033 Lampe_Colon cancer biomarkers.pdf

colon-cancer-biomarkers-14-033